Taiga Biotechnologies, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2006-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.taigabiotech.com
Clinical Trials
4
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (100.0%)Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis
Phase 1
Not yet recruiting
- Conditions
- Acute Myelogenous LeukemiaMyelofibrosis
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- Taiga Biotechnologies, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT04709458
- Locations
- 🇭🇷
University Hospital Centre Zagreb, Zagreb, Croatia
🇮🇹Fondazione Policlinico Universitario Agostino Gemelli, Roma, Italy
Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies
Phase 1
- Conditions
- Tumor, SolidCancerRefractory Cancer
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- Taiga Biotechnologies, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT04640246
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇮🇱Rabin Medical Center, Petach Tikva, Israel
Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors
Phase 1
Recruiting
- Conditions
- Stage IV MelanomaStage III Melanoma
- First Posted Date
- 2017-12-28
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- Taiga Biotechnologies, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT03385486
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸University of Colorado Cancer Center, Denver, Colorado, United States
Safety and Early Efficacy Study of TBX-1400 in Patients With Severe Combined Immunodeficiency
Phase 1
- Conditions
- Severe Combined Immunodeficiency
- First Posted Date
- 2016-08-09
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Taiga Biotechnologies, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT02860559
- Locations
- 🇮🇱
Hadassah Medical Center (Ein Kerem site), Jerusalem, Israel
🇮🇱Schneider Children's Medical Center, Petach Tikva, Israel
News
No news found